Filing Details
- Accession Number:
- 0001177648-21-000027
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-10-13 18:39:01
- Reporting Period:
- 2021-10-08
- Accepted Time:
- 2021-10-13 18:39:01
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1177648 | Enanta Pharmaceuticals Inc | ENTA | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1646976 | Nathalie Adda | C/O Enanta Pharmaceuticals, Inc. 500 Arsenal Street Watertown MA 02472 | Sr. Vp & Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-10-08 | 13,453 | $43.46 | 40,397 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-10-08 | 13,453 | $70.09 | 26,944 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2021-10-11 | 4,047 | $43.46 | 30,991 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-10-11 | 4,047 | $70.34 | 26,944 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2021-10-08 | 13,453 | $0.00 | 13,453 | $43.46 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2021-10-11 | 4,047 | $0.00 | 4,047 | $43.46 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
58,817 | 2025-06-29 | No | 4 | M | Direct | |
54,770 | 2025-06-29 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.30, inclusive.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.05 to $70.85, inclusive.
- 100% of the shares subject to the option are fully vested and exercisable.